An Insider Matthew Sherman Unloaded 4600 shares of Acceleron Pharma Inc. (XLRN); Lyondellbasell Industries NV Has 0.91 Sentiment

April 5, 2018 - By Danny Collins

Acceleron Pharma Inc. (NASDAQ:XLRN) Logo

Lyondellbasell Industries NV (LYB) investors sentiment increased to 0.91 in 2017 Q4. It’s up 0.07, from 0.84 in 2017Q3. The ratio has increased, as 294 investment managers opened new or increased positions, while 322 reduced and sold their holdings in Lyondellbasell Industries NV. The investment managers in our database now own: 288.04 million shares, up from 287.42 million shares in 2017Q3. Also, the number of investment managers holding Lyondellbasell Industries NV in top ten positions decreased from 14 to 11 for a decrease of 3. Sold All: 51 Reduced: 271 Increased: 206 New Position: 88.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $1.74 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

The EVP & Chief Medical Officer of Acceleron Pharma Inc, Matthew Sherman is in the stock market news today. It was published in a legal form filled by Matthew Sherman and submitted to the SEC on 04-04-2018, he unloaded 4,600 shares from the firm worth $176,772 USD. The reported shares average price was $38.4. Matthew Sherman presently has ownership of 77,267 shares which make up precisely 0.17% of the Massachusetts-based company’s market cap.

The stock increased 0.55% or $0.21 during the last trading session, reaching $38.35. About 813,806 shares traded or 162.37% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 45.87% since April 5, 2017 and is uptrending. It has outperformed by 34.32% the S&P500.

Investors sentiment decreased to 1.09 in 2017 Q4. Its down 0.72, from 1.81 in 2017Q3. It worsened, as 24 investors sold Acceleron Pharma Inc. shares while 32 reduced holdings. 14 funds opened positions while 47 raised stakes. 38.14 million shares or 1.07% more from 37.73 million shares in 2017Q3 were reported. Evercore Wealth Limited Liability Corporation has invested 0.05% in Acceleron Pharma Inc. (NASDAQ:XLRN). Great West Life Assurance Co Can accumulated 5,080 shares or 0% of the stock. Bailard Inc reported 8,000 shares. Nelson Van Denburg & Campbell Wealth Management Limited Liability holds 4,540 shares or 0.04% of its portfolio. Moreover, Platinum Inv Mgmt Limited has 0.07% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 58,500 shares. 15,164 are owned by Congress Asset Mngmt Ma. Birchview Lp invested in 0.62% or 25,000 shares. Td Asset Mgmt, a Ontario – Canada-based fund reported 61,500 shares. Ubs Asset Mngmt Americas, a Illinois-based fund reported 435,363 shares. Perceptive Advsrs Ltd Co reported 2.27% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Farallon Capital Mngmt Ltd Liability Co, California-based fund reported 1.09M shares. Moreover, Artisan Prns Limited Partnership has 0.03% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Moreover, Swiss Commercial Bank has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 62,300 shares. 4,662 are held by C Grp A S. Pnc Svcs Gru Incorporated, Pennsylvania-based fund reported 8,212 shares.

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 12 have Buy rating, 1 Sell and 3 Hold. Therefore 75% are positive. Acceleron Pharma has $63 highest and $20 lowest target. $45.71’s average target is 19.19% above currents $38.35 stock price. Acceleron Pharma had 40 analyst reports since August 13, 2015 according to SRatingsIntel. The company was initiated on Monday, January 8 by H.C. Wainwright. Citigroup maintained Acceleron Pharma Inc. (NASDAQ:XLRN) on Thursday, March 1 with “Buy” rating. The firm has “Buy” rating given on Tuesday, June 13 by FBR Capital. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Outperform” rating by Credit Suisse on Thursday, January 21. The firm has “Buy” rating given on Friday, October 6 by Piper Jaffray. On Monday, February 26 the stock rating was upgraded by JP Morgan to “Overweight”. As per Thursday, December 17, the company rating was initiated by Janney Capital. RBC Capital Markets maintained Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Thursday, November 2. RBC Capital Markets has “Hold” rating and $44.0 target. The company was maintained on Wednesday, September 20 by Barclays Capital. The rating was downgraded by Oppenheimer on Tuesday, June 13 to “Market Perform”.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on May, 14. They expect $-0.64 earnings per share, up 3.03% or $0.02 from last year’s $-0.66 per share. After $-0.62 actual earnings per share reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts 3.23% negative EPS growth.

Since December 15, 2017, it had 0 insider purchases, and 8 sales for $7.28 million activity. $183,806 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Quisel John D on Tuesday, January 2. The insider Kumar Ravindra sold 4,300 shares worth $182,363. 19,000 shares valued at $814,848 were sold by MCLAUGHLIN KEVIN F on Tuesday, January 2. George Jean also sold $3.76 million worth of Acceleron Pharma Inc. (NASDAQ:XLRN) shares. 2,266 shares valued at $96,134 were sold by Rovaldi Christopher on Tuesday, January 2. $197,868 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Sherman Matthew L on Wednesday, January 3. POPS RICHARD F had sold 37,500 shares worth $1.55 million.

Analysts await LyondellBasell Industries N.V. (NYSE:LYB) to report earnings on April, 27. They expect $2.81 earnings per share, up 24.34% or $0.55 from last year’s $2.26 per share. LYB’s profit will be $1.11 billion for 9.14 P/E if the $2.81 EPS becomes a reality. After $2.73 actual earnings per share reported by LyondellBasell Industries N.V. for the previous quarter, Wall Street now forecasts 2.93% EPS growth.

The stock decreased 1.35% or $1.41 during the last trading session, reaching $102.73. About 4.71M shares traded or 96.80% up from the average. LyondellBasell Industries N.V. (LYB) has risen 17.51% since April 5, 2017 and is uptrending. It has outperformed by 5.96% the S&P500.

Cincinnati Indemnity Co holds 7% of its portfolio in LyondellBasell Industries N.V. for 16,134 shares. Csu Producer Resources Inc. owns 12,334 shares or 5.92% of their US portfolio. Moreover, Kirr Marbach & Co Llc In has 4.18% invested in the company for 188,525 shares. The Maine-based Bar Harbor Trust Services has invested 3.82% in the stock. Mrj Capital Inc, a New York-based fund reported 54,200 shares.

Ratings analysis reveals 20% of LyondellBasell’s analysts are positive. Out of 5 Wall Street analysts rating LyondellBasell, 1 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $83.0 while the high is $95.0. The stock’s average target of $89.33 is -13.04% below today’s ($102.73) share price. LYB was included in 5 notes of analysts from September 13, 2016. The rating was maintained by RBC Capital Markets with “Sector Perform” on Monday, February 6. The firm earned “Hold” rating on Tuesday, September 13 by Deutsche Bank. As per Thursday, December 29, the company rating was maintained by Cowen & Co. The stock of LyondellBasell Industries N.V. (NYSE:LYB) has “Buy” rating given on Friday, October 14 by Tudor Pickering. On Friday, February 10 the stock rating was downgraded by Susquehanna to “Neutral”.

LyondellBasell Industries N.V. operates as a maker of chemicals and polymers, refiner of crude oil, producer of gasoline blending components, and developer and licensor of technologies for production of polymers worldwide. The company has market cap of $40.53 billion. The firm operates in five divisions: Olefins and Polyolefins—Americas; Olefins and Polyolefins—Europe, Asia, International; Intermediates and Derivatives; Refining; and Technology. It has a 8.4 P/E ratio. It produces and markets olefins, including ethylene, propylene, and butadiene; polyethylene products, which consist of high density polyethylene, low density polyethylene, and linear low density polyethylene; polyolefins, such as polyethylene and polypropylene ; and PP homopolymers, copolymers, and compounds.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart